COVID-19 was the likely trigger of atypical hemolytic uremic syndrome (aHUS) in a boy found to carry a mutation that reduced the levels of an immune protein called CD46, which may have increased his chance of developing the disease, according to a report from Iran. The boy first improved…
The pregnancy-related complication HELLP syndrome — fully known as hemolysis, elevated liver enzymes, and low platelets syndrome, which causes high blood pressure and organ damage — is sometimes confused with atypical hemolytic uremic syndrome, or aHUS, a rare disease in which kidney dysfunction persists for a long time, especially…
Soliris (eculizumab) largely reduces the risk of long-term kidney problems in women who develop atypical hemolytic uremic syndrome (aHUS) during or after pregnancy, a meta-analysis study has found. “This analysis highlights the severe kidney and pregnancy outcomes associated with [pregnancy-associated aHUS],” researchers wrote, noting Soliris treatment is beneficial…
The use of a C5 inhibitor — with or without plasma exchange — was found to work better than supportive care to treat kidney problems in women who develop atypical hemolytic uremic syndrome (aHUS) as a complication of bleeding after giving birth, a study found. However, the researchers noted…
Genetic testing may allow for the timely use of anti-complement therapy for atypical hemolytic uremic syndrome (aHUS), even if an infection with Shiga toxin-producing Escherichia coli (STEC), a trigger of the typical form of the disease, is present and initially upstages the correct diagnosis of aHUS. In a…
The use of Soliris (eculizumab) is changing the natural course of atypical hemolytic uremic syndrome (aHUS) in Latin America as it has in other regions, helping many patients achieve better outcomes, according to a review study. While aHUS arises from the same genetic causes and manifests in a…
Adults with atypical hemolytic uremic syndrome (aHUS) who switched from Soliris (eculizumab) to long-acting Ultomiris (ravulizumab) in a real-world setting experienced no new side effects or worsening of symptoms for up to a year, a study has found. Switching to Ultomiris may be more convenient for patients…
The U.S. Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb), the first interchangeable biosimilar to Soliris (eculizumab), to treat people with atypical hemolytic uremic syndrome (aHUS). A biosimilar is a medication highly similar to a reference biologic — a medication made from natural, living sources like bacteria —…
In a young girl, thrombotic microangiopathy — a group of disorders, including atypical hemolytic uremic syndrome (aHUS), that are marked by organ damage caused by the formation of blood clots inside small blood vessels — occurred secondary to a sudden spike in blood pressure. Because the opposite is more…
A team of five experts from across Spain got together to reach a consensus on a set of recommendations for how to best manage atypical hemolytic uremic syndrome (aHUS) in adults. The consensus offers guidance for doctors with less experience in managing the disease. It covers the entire patient…
Get regular updates to your inbox.